Targeting the Pathways to Better Health
Our Mission
Intellikine is discovering and developing best-in-class
small molecule drugs that target signal transduction networks
for the treatment of cancer and others diseases. Learn
More
Bio Partnering Europe
October 10-12 / London, UK
22nd EORTC-NCI-AACR Symposium
November 16-19 / Berlin, Germany
Learn More
Our pipeline programs include both novel isoform-selective and pathway-selective inhibitors of members of the PI3K/Akt/mTOR signaling network.
Learn More
Infinity Licenses PI3K Program From Intellikine in $489M Deal
Learn More